Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 9:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 41 matching trials from the live ClinicalTrials.gov search.
Conditions
Episodic Migraine
Interventions
Bupivacaine HCl 0.5% Injectable Solution, Methylprednisolone 40 MG Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Osteoarthritis
Interventions
Bupivacaine, Morphine, Methylprednisolone, Cefazolin, Normal saline, Midazolam, Propofol, Dexamethasone, 8 MHz. Chiba needle, 22 G / 4 inches
Drug · Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Morton's Neuroma
Interventions
Resiniferatoxin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Pain Assessment, Quality of Life (QOL), Analgesic Use
Interventions
Supplemental Postoperative Bupivacaine, Placebo Injection
Drug
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Total Knee Arthroplasty
Interventions
Peripheral nerve blocks with Bupivacaine, Intra articular injection with Ropivacaine, Intra articular injection with liposomal bupivacaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Rotator Cuff Tears, Shoulder Pain
Interventions
Liposomal bupivacaine, Bupivacaine Hcl 0.5% Inj, Ropivacaine 0.5% Injectable Solution, Dexamethasone
Drug
Lead sponsor
Hospital for Special Surgery Florida
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
West Palm Beach, Florida
Not listed Phase 3 Interventional Accepts healthy volunteers

Pain Relief After PrimaryTKA

NCT05751421
Conditions
Pain, Postoperative
Interventions
Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution, Bupivacaine HCl 0.5% Injectable Solution, primary total knee replacement
Drug · Procedure
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cervical Spine Fusion
Interventions
Bupivacaine Hcl 0.25% Inj, Normal saline
Drug · Other
Lead sponsor
Hartford Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Conditions
Pain, Postoperative, Morbid Obesity
Interventions
Injected bupivacaine post-operatively, Streamed bupivacaine versus streamed normal saline, Aerosolized bupivacaine versus aerosolized saline, Injected lidocaine pre-incision vs saline pre-incision
Drug
Lead sponsor
Pinnacle Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Harrisburg, Pennsylvania
Conditions
Post-operative Pain
Interventions
Bupivicaine, placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Pain, Postoperative, Amputation
Interventions
Liposomal bupivacaine, Bupivacaine Hydrochloride 0.5 % Injectable Solution
Drug
Lead sponsor
Aurora Quaye
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Portland, Maine
Conditions
Post Operative Pain
Interventions
Bupivacaine 0.5% Injectable Solution, Ropivacaine 0.2% Injectable Solution, 1.3% liposomal bupivacaine (Exparel), ambIT Infusion Pump
Drug · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Somerset, New Jersey
Conditions
Pain
Interventions
Marcaine 0.25 % Injectable Solution
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
16 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Completed Phase 3 Interventional Results available

Pediatric Tonsillectomy Pain Reduction Study

NCT00678379
Conditions
Postoperative Pain
Interventions
lidocaine (1%) + bupivacaine (0.5%), Normal saline, Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
3 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Pain
Interventions
Bipivacaine 0.5% with epinephrine, Normal Saline
Drug
Lead sponsor
Souza, Amanda, M.D.
Individual
Eligibility
21 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Farmington Hills, Michigan
Conditions
Hallux Valgus
Interventions
TLC590, Naropin®, Normal Saline, Bupivacaine
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
Conditions
Degenerative Joint Disease
Interventions
Group A (corticosteroid injection group), Group B (platelet rich plasma injection group)
Drug · Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Los Angeles, California